JESSE VINER: Open Payments
NPI 1568427334 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,386 in 42 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $1,386
Food & beverage: $1,386
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 9 | $275 |
| Gilead Sciences, Inc. | 2 | $264 |
| ABBVIE INC. | 14 | $243 |
| Ipsen Biopharmaceuticals, Inc | 5 | $191 |
| Novo Nordisk Inc | 1 | $118 |
| GENZYME CORPORATION | 1 | $117 |
| QOL Medical, LLC | 3 | $81 |
| Phathom Pharmaceuticals, Inc. | 3 | $28 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Madrigal Pharmaceuticals | 1 | $18 |
Products named: TREMFYA, DUPIXENT, RINVOQ, Epclusa, Bylvay, Sucraid, IQIRVO, SKYRIZI.
Industry payments across NV — which companies pay providers there.
